GlassScriptPhysician profile
Joseph Carl Smiddy
NPI 1841246006
$8,190.14
in general payments reported to CMS, 2019-2025
43 companies · $1,557 in 2025
The $1,557 reported for 2025 was more than what 91% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,071 · 2020: $652 · 2021: $676 · 2022: $1,822 · 2023: $1,029 · 2024: $1,383 · 2025: $1,557.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,969.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,969.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $1,818.86 | 2019-2025 | Biktarvy |
| Viiv Healthcare Company | $1,407.03 | 2019-2025 | Cabenuva, Apretude, Dovato |
| Merck Sharp & Dohme LLC | $809.04 | 2019-2025 | Pifeltro, Delstrigo, Dificid |
| Lilly USA, LLC | $633.34 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Abbvie INC. | $501.11 | 2021-2025 | Vraylar |
| Janssen Biotech, INC. | $412.45 | 2019-2023 | Symtuza |
| Takeda Pharmaceuticals U.S.A., INC. | $319.24 | 2019-2024 | Trintellix |
| Novo Nordisk INC | $259.70 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Theratechnologies INC. | $245.38 | 2021-2025 | Egrifta, Trogarzo |
| Astrazeneca Pharmaceuticals LP | $207.92 | 2019-2025 | Airsupra |
| Napo Pharmaceuticals INC | $167.85 | 2019-2025 | Mytesi |
| Exact Sciences Corporation | $127.77 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Allergan, INC. | $118.77 | 2019-2020 | |
| Axsome Therapeutics, INC. | $92.67 | 2023-2025 | Auvelity |
| Supernus Pharmaceuticals, INC. | $85.69 | 2022-2024 | Qelbree, Xyosted |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Smiddy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.